Magnus Life Science today announces that the European Medicines Agency's Committee for Orphan Medicinal Products has reached a positive decision on recommending orphan designation to Magnus Growth's novel therapy to treat placental insufficiency.
from The Medical News http://ift.tt/1tN1AC9
from The Medical News http://ift.tt/1tN1AC9
No comments:
Post a Comment